IP Library › Granted Patent US 10,072,247
Granted Patent B2
US 10,072,247 · App. 14/433,495 · Granted Sep 11, 2018

Composition comprising ischemic serum for promoting activation of stem cell and method for promoting activation of stem cell

Inventors: Oh Young Bang (Seoul, KR); Gyeong Joon Moon (Seongnam-si, KR); Yeon Hee Cho (Seoul, KR); Suk Jae Kim (Seoul, KR); Dong Hee Kim (Seoul, KR); Soo Kyung Ryoo (Seoul, KR); Ji Hyun Lee (Busan, KR); Ji Yoon Nam (Seoul, KR); Ji Hee Sung (Seoul, KR)
Assignee: Samsung Life Public Welfare Foundation
C12N5/0663A61K35/16A61K35/28A61K2035/124C12N2500/84
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,072,247
App. No.
14/433,495
Granted
Sep 11, 2018
Kind
B2
Abstract

The present invention relates to a composition comprising an ischemic serum for promoting the activation of a stem cell, to a method for promoting the activation of a stem cell and to a stem cell, the activation of which is promoted by the composition or the method. The ischemic serum according to the present invention may stimulate the stem cell to facilitate the secretion of a growth factor, improve survival rate, improve mobility to an injured part, improve proliferation rate and maintain characteristics of the stem cell, thus promoting an activation of the stem cell such that the stem cell becomes suitable for transplantation of the stem cell to a patient having a brain injury.

Claims (6)

1. A method for promoting the activation of mesenchymal stem cells, comprising the step of treating mesenchymal stem cells obtained from normal subjects with allogenic ischemic serum obtained from a patient with cerebral infarction,

wherein the activation of mesenchymal stem cells comprises increased gene expression of growth factors, decreased gene expression of brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF); and

wherein the growth factors comprise endothelial growth factor (VEGF), glial cell-derived neurotrophic factor (GDNF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF).

2. The method of claim 1 , wherein the ischemic serum is obtained from a patient within 1 to 90 days after the onset of cerebral infarction.

3. The method of claim 1 wherein the treating of mesenchymal stem cells comprises culturing mesenchymal stem cells in a medium containing ischemic serum.

4. The method of claim 3 , wherein the ischemic serum is contained in a concentration of 5 to 20%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2015
From: BANG, OH YOUNG; MOON, GYEONG JOON; CHO, YEON HEE; KIM, SUK JAE; KIM, DONG HEE; RYOO, SOO KYUNG; LEE, JI HYUN; NAM, JI YOON; SUNG, JI HEE
To: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
Reel/Frame 035683/0572 →
Priority Claims (1)
KR 10-2012-0110876 · Oct 5, 2012 · national
Continuity (1)
Related Publication 20150337264A1 · Nov 26, 2015